Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management
- PMID: 29892142
- PMCID: PMC5993897
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management
Abstract
Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovulation induction that usually occurs after gonadotropin stimulation, followed by human chorionic gonadotropin administration, for infertility treatment. The existing knowledge about the pathophysiology, risk factors, and primary and secondary methods for the prevention of OHSS is reviewed in this manuscript. The clinical manifestations and characteristics of mild, moderate, severe, and critical forms of the syndrome are defined. The methods of handling affected cases as outpatient or in-hospital management methods as well as indications for hospitalization are summarized in this review. The clinical and biochemical routes of assessing and monitoring hospitalized patients with OHSS, various drugs and medical treatment strategies including indications for aspiration of the ascitic fluid and pleural effusion, and also rare indications for surgery are briefly explained in this article. Severe OHSS, which two decades ago was considered an iatrogenic life-threatening condition, can now be effectively prevented or managed during the early stages. An OHSS-free clinic can be established nowadays by carefully considering the endocrinology of ovulation and using appropriate and dose-adjusted pharmaceutical agents, which are summarized and discussed in this review.
Keywords: Classification; Fertilization in vitro; Pathophysiology; Prevention; Risk factors; Ovarian hyperstimulation syndrome.
Conflict of interest statement
Conflict of Interest: None declared.
Similar articles
-
The prevention of ovarian hyperstimulation syndrome.J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. J Obstet Gynaecol Can. 2014. PMID: 25574681 Review. English, French.
-
Modern management of ovarian hyperstimulation syndrome.Hum Reprod. 1991 Sep;6(8):1082-7. doi: 10.1093/oxfordjournals.humrep.a137488. Hum Reprod. 1991. PMID: 1806565 Review.
-
Ovarian hyperstimulation syndrome.Crit Care Med. 2005 Oct;33(10 Suppl):S301-6. doi: 10.1097/01.ccm.0000182795.31757.ce. Crit Care Med. 2005. PMID: 16215351 Review.
-
[Ovarian hyperstimulation syndrome--a risk of treatment for infertility].Nord Med. 1997 Sep;112(7):236-9. Nord Med. 1997. PMID: 9380489 Danish.
-
Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.J Ovarian Res. 2019 Jan 26;12(1):8. doi: 10.1186/s13048-019-0483-7. J Ovarian Res. 2019. PMID: 30684970 Free PMC article. Clinical Trial.
Cited by
-
Comparison of Steroidogenic and Ovulation-Inducing Effects of Orthosteric and Allosteric Agonists of Luteinizing Hormone/Chorionic Gonadotropin Receptor in Immature Female Rats.Int J Mol Sci. 2023 Nov 22;24(23):16618. doi: 10.3390/ijms242316618. Int J Mol Sci. 2023. PMID: 38068943 Free PMC article.
-
The value of ovarian hyperstimulation syndrome in predicting pregnancy outcome in women with polycystic ovarian syndrome and candidate for in vitro fertilization: A case-control study.Int J Reprod Biomed. 2023 Dec 19;21(11):921-928. doi: 10.18502/ijrm.v21i11.14655. eCollection 2023 Nov. Int J Reprod Biomed. 2023. PMID: 38292512 Free PMC article.
-
Right atrial thrombus and pulmonary thromboembolism related to ovarian hyperstimulation syndrome: A case report and literature review.Clin Case Rep. 2023 Mar 7;11(3):e7018. doi: 10.1002/ccr3.7018. eCollection 2023 Mar. Clin Case Rep. 2023. PMID: 36911649 Free PMC article.
-
Assisted Reproductive Technology or Infertility: What underlies adverse outcomes? Lessons from the Massachusetts Outcome Study of Assisted Reproductive Technology.F S Rev. 2022 Oct;3(4):242-255. doi: 10.1016/j.xfnr.2022.06.003. Epub 2022 Jul 5. F S Rev. 2022. PMID: 36505962 Free PMC article.
-
Clinical Pregnancy and Incidence of Ovarian Hyperstimulation Syndrome in High Ovarian Responders Receiving Different Doses of hCG Supplementation in a GnRH-Agonist Trigger Protocol.Evid Based Complement Alternat Med. 2021 Oct 25;2021:2180933. doi: 10.1155/2021/2180933. eCollection 2021. Evid Based Complement Alternat Med. 2021. Retraction in: Evid Based Complement Alternat Med. 2023 Jun 21;2023:9814583. doi: 10.1155/2023/9814583. PMID: 34733337 Free PMC article. Retracted.
References
-
- Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901–7. - PubMed
-
- Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482–9. - PubMed
-
- Whelan JG, 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–96. - PubMed
-
- Naredi N, Talwar P, Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. Med J Armed Forces India. 2014;70:58–63. doi: 10.1016/j.mjafi.2012.03.005. [ PMC Free Article] - DOI - PMC - PubMed
-
- Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 2013;4:58–63. doi: 10.3389/fendo.2013.00150. [ PMC Free Article] - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources